Hummsa Biotech

1 known investors

Hummsa Biotech develops next-generation oral GLP-1 receptor agonist therapies targeting the root causes of obesity, diabetes, and related metabolic and chronic diseases. Its lead candidate, HB PKO02, is an oral small molecule designed to regenerate insulin-producing beta cells to restore function and enable prevention rather than symptom management.